Embecta Corp
embecta.comEmbecta Corp (NASDAQ: EMBC) is a medical device company focused on diabetes care that manufactures and sells drug delivery devices used by people living with diabetes. Revenue is generated through transactional product sales of injection and delivery devices distributed across global healthcare channels. Embecta was spun off from Becton, Dickinson and Company and operates as an independent company listed on the Nasdaq Global Select Market. The company serves an end market shaped by a growing global diabetic population and a secular shift in chronic care delivery from hospitals to primary care settings. As of September 30, 2025, Embecta held $228.6 million in cash and equivalents and restricted cash, generated $191.7 million in operating cash flow in FY2025, and carried net income of $95.4 million. The capital structure is debt-heavy, with $184.6 million in long-term debt payments made during FY2025. Credit ratings as of mid-2025 stand at B1 from Moody's and B+ from Standard and Poor's. The company declares dividends, with $35.0 million in dividend payments made during FY2025.
Products & Services
Diabetes drug delivery devices including injection devices, subject to FDA regulation governing design, manufacturing, labeling, and distribution.
Revenue Model
Transactional product sales of diabetes drug delivery devices sold through healthcare distribution channels globally.
Customers & Markets
People living with diabetes and the healthcare providers serving them, including primary care providers. End market demand is driven by a growing and aging global diabetic population. Emerging markets represent a portion of the geographic footprint, with associated political and economic variability.
Geographic Exposure
Global operations including the United States and multiple emerging markets. Subject to foreign regulatory requirements, data localization laws, and tariff exposure given international manufacturing and distribution footprint.
Financial Snapshot
Loading...
